AKTX
Akari Therapeutics, Plc
NASDAQ · Healthcare · Biotechnology · GB
$11.77
+8.58%Aug 18, 2026, 12:53 UTC
Akari Therapeutics announced that AKTX-101, its antibody-drug conjugate, demonstrated robust anti-tumor activity in preclinical urothelial cancer models, supporting its differentiated ADC strategy.
Source:Aug 13, 2026, 00:00 UTC
Akari Therapeutics Plc reported a net loss of $4.8 million for Q2 2026, compared to a net loss of $1.9 million in Q2 2025, with research and development expenses rising to $2.1 million from $0.7 million year-over-year.
Jul 21, 2026, 11:05 UTC
Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics.
Source:Jun 29, 2026, 12:45 UTC
Akari Therapeutics completed a $5.5 million PIPE led by existing investors and received $2.8 million from warrant exercises, raising approximately $8.3 million in Q2 2026.
Source: